Scleroderma

Background

  • Autoimmune collagen vascular disease, aka Systemic Sclerosis
  • Inappropriate and excessive accumulation of collagen and matrix in various tissues
  • Widespread vascular lesions
    • Endothelial dysfunction
    • Vascular spasm
    • Vascular wall thickening
    • Narrowed lumen
  • Two types, Diffuse and Limited
    • Diffuse Systemic Sclerosis: Skin changes, which can progress to internal organ involvement
    • Limited Cutaneous Systemic Sclerosis, aka "CREST Syndrome"

Clinical Features

  • Systemic complaints (fever, malaise, fatigue, weight loss, myalgias)
  • Diffuse Systemic Sclerosis
    • hypo- or hyper- pigmentation of skin, extending from fingers and toes proximally, also involving chest and abdominal wall
    • Pigment is perserved around hair follicles leading to salt and pepper appearance
      Hypopigmentation in Diffuse Scleroderma, courtesy of Regional Derm website
    • Symmetric hand edema and Raynaud's phenomenon
    • Abrupt Disease presentation; worse in first 18 months then improvement or worsening to involve internal organs
  • Liminted Sytemic Sclerosis, aka "CREST Syndrome"
    • Longstanding Raynaud's
    • Skin thickening and fibrosis distal to elbows and knees, and on face
    • Subcutaneous calcinosis
    • Esophageal dysmotility
    • Sclerodactyly
    • Telangiectasia
    • Indolent course

Emergencies

  • Renal Crisis
    • Causes are vessel narrowing and subsequent ischemic kidney disease
    • Lead to hypertensive emergency, acute renal failure, and microangiopathic hemolytic anemia
    • Occurs during first 5 years of the disease
    • Treatment is strict BP control - ACEI drug of choice
      • Was the most common cause of death prior to ACEi usage[1]
    • Severe renal crisis is life threatening with incidence of 8-10% in Limited and 10-20% in diffuse
      • Similar to TTP/HUS with microangiography
      • Poor prognosis with sudden onset of hypertension, encephalopathy, CVA, retinopathy
      • Risk factors are rapidly progressing Diffuse Scleroderma, high dose glucocorticoid use, cyclosporin therapy, presence of anti-RNA-polymerase antibodies.[2]
  • Pulmonary
    • Respiratory failure
    • Interstitial Lung Disease, leading to pulmonary fibrosis
      • Found in dorsal portion of both lower lobes, but can extend to upper lobes in severe diease
      • Poor prognosis with severe pulmonary impairment. 42% die within 10 years of disease onset[3]
    • ARDS
    • Aspiration pneumonitis
    • Pulmonary hypertension
      • Gradually progressive exercise breathlessness
      • Fatigue
      • Anginal pain from right ventricle ischemia and low cardiac output
      • Hoarseness from nerve palsy caused by dilated pulmonary artery stem
    • Alveolar hemorrhage
  • Cardiac

Differential Diagnosis

Evaluation

  • Frequent blood pressure checks
  • Serologic markers for each subset
  • Renal Crisis
    • Urinalysis for proteinuria or hematuria
    • Basic Metabolic Panel
    • Chest Xray for pulmonary edema
  • Pulmonary Arterial Hypertension
    • Basic labs, including troponin
    • Echo to evaluate right heart and estimation of right atrial pressure
    • Right heart catheterization indicated in symptomatic patients
  • Interstitial Lung Diease
    • Frequent checks of FVC to monitor disease
    • Chest xray, CT of the chest
    • Lung biopsy
  • CREST Syndrome
    • Endoscopy and Hemoccult test to evaluate for blood loss from mucosal telangiectasias (gastric antral vascular ectasia, described as "watermelon stomach."


Management

  • Renal Crisis
    • Rapid control of blood pressure
    • Start on ACE Inhibitor, captopril 6.25 to 12.5mg PO, TID.
    • Avoid diuretics
    • Consult Nephrology, as 50% of patients will require dialysis.
  • Pulmonary Arterial Hypertension
    • Warfarin to prevent Pulmonary Embolism
    • Endothelin-I receptor antagonist, phosphodiesterase inhibitor or IV prostanoids
  • Interstitial Lung Disease
    • lower dose glucocorticoid
    • cyclophosphamide
    • May require ventilatory support (NIPPV or Intubation)
  • CREST Syndrome
    • Empiric treatment with a PPI to prevent reflux and stricture formation
    • Blood replacement if chronic loss from mucosal telangiectasias
    • Ursodial treatment if concomitant primary biliary cirrhosis to prevent progression to secondary cirrhosis

Disposition

  • Hospitalization for any elevation in blood pressure, difficulty breathing, evidence of heart strain or pulmonary edema.
  • Consult Rheumatology
  • Consult Pulmonary
  • Consult Nephrology

See Also

References

  1. Komocsi A, Vorobcsuk A, Faludi R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012;51:1027–1036
  2. Vymetal J, Skacelova M, Smrzova A, Klicova A, Schubertova M, Horak P, Zadrazil J. Emergency situations in rheumatology with a focus on systemic autoimmune diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):20-9. doi: 10.5507/bp.2016.002. Epub 2016 Feb 10. Review. PubMed PMID: 26868300.
  3. Luo Y, Xiao R. Interstitial Lung Disease in Scleroderma: Clinical Features and Pathogenesis. Rheumatology 2011 doi:10.4172/2161- 1149. S1-002. Available from: http://omicsonline.org/ interstitial-lung-disease-in-scleroderma-clinical-features-and- pathogenesis-2161-1149.S1-002.pdf
  4. Nikpour, M., Baron, M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol. 2014;26:131–137
  5. Komocsi A, Vorobcsuk A, Faludi R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012;51:1027–1036
  6. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–15. doi: 10.1136/ard.2009.114264